Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis
Publication
, Conference
Buechner, J; Grupp, SA; Maude, SL; Boyer, M; Bittencourt, H; Laetsch, TW; Bader, P; Verneris, MR; Stefanski, H; Myers, GD; Qayed, M; Schlis, K ...
Published in: Clinical Lymphoma Myeloma and Leukemia
September 2017
Duke Scholars
Published In
Clinical Lymphoma Myeloma and Leukemia
DOI
ISSN
2152-2650
Publication Date
September 2017
Volume
17
Start / End Page
S263 / S264
Publisher
Elsevier BV
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Buechner, J., Grupp, S. A., Maude, S. L., Boyer, M., Bittencourt, H., Laetsch, T. W., … Rives, S. (2017). Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis. In Clinical Lymphoma Myeloma and Leukemia (Vol. 17, pp. S263–S264). Elsevier BV. https://doi.org/10.1016/j.clml.2017.07.030
Buechner, Jochen, Stephan A. Grupp, Shannon L. Maude, Michael Boyer, Henrique Bittencourt, Theodore W. Laetsch, Peter Bader, et al. “Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis.” In Clinical Lymphoma Myeloma and Leukemia, 17:S263–64. Elsevier BV, 2017. https://doi.org/10.1016/j.clml.2017.07.030.
Buechner J, Grupp SA, Maude SL, Boyer M, Bittencourt H, Laetsch TW, et al. Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis. In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2017. p. S263–4.
Buechner, Jochen, et al. “Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis.” Clinical Lymphoma Myeloma and Leukemia, vol. 17, Elsevier BV, 2017, pp. S263–64. Crossref, doi:10.1016/j.clml.2017.07.030.
Buechner J, Grupp SA, Maude SL, Boyer M, Bittencourt H, Laetsch TW, Bader P, Verneris MR, Stefanski H, Myers GD, Qayed M, Pulsipher MA, De Moerloose B, Hiramatsu H, Schlis K, Davis K, Martin PL, Nemecek E, Peters C, Wood P, Taran T, Mueller KT, Zhang Y, Rives S. Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis. Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2017. p. S263–S264.
Published In
Clinical Lymphoma Myeloma and Leukemia
DOI
ISSN
2152-2650
Publication Date
September 2017
Volume
17
Start / End Page
S263 / S264
Publisher
Elsevier BV
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences